Semler Scientific, Inc. (SMLR) research, news, and more from GeoInvesting

Company description

Fri, 20 Apr 2018 15:50:19 GMT

Semler Scientific, Inc. develops, manufactures, and markets patented products that assist healthcare providers to evaluate and treat patients with chronic diseases in the United States. Its products include QuantaFlo, a four-minute in-office blood flow test that enables healthcare providers to use blood flow measurements as part of their examinations of a patient's vascular condition; and WellChec, a multi-test service platform to evaluate patients with various chronic diseases. The company's products serve cardiologists, internists, nephrologists, endocrinologists, podiatrists, and family practitioners, as well as organizations, including healthcare insurance plans, integrated delivery networks, independent physician groups, and companies contracting with the healthcare industry; and other healthcare organizations, such as risk assessment groups and other home healthcare providers. It offers its products through salespersons and distributors. Semler Scientific, Inc. was founded in 2007 and is headquartered in San Jose, California.

PodClips

Sun, 20 Aug 2023 04:00:00 GMT

Our research update on SMLR revolves around trying to gain more of an understanding on how the unfavorable changes in Medicare and Medicaid reimbursement for the company's medical device that tests for pulmonary disease (PAD) will impact future revenues.

Research

Mon, 14 Aug 2023 18:23:16 GMT

Semler Scientific (OOTC:SMLR), a company that offers technology and software solutions to healthcare providers, announced Q2 2023 results:

Sales of $18.6 million vs $14.8 million in the prior year, ahead of analyst estimates of $16.0 million
EPS of $0.75 vs $0.51 in the prior year and beats analyst estimates of $0.56

"We are pleased to report once again record quarterly revenues and pre-tax net income predominately from sales of QuantaFlo® for peripheral arterial disease testing," said Doug Murphy-Chutorian, MD, chief executive officer of Semler Scientific. "We are encouraged by our results year to date and are highly focused on developing our business in heart dysfunction."

See our weekly wrap email from July 23, 2023 where we highlight SMLR as one of our most successful contributor picks. The stock is well off highs due to the company announcing that Medicare and Medicaid reimbursement will be a lot less or a limited amount for one of its medical testing devices. We’re extremely interested in tracking SMLR.

The conference call did not go into detail of the potential impact from the medicare/medicaid decision. The company stated it continues to focus on maintaining and enhancing revenue and profitability opportunities.

“Our primary objective remains steadfast to maintain and enhance our current revenue opportunities and profitability. To achieve this, we are reinvesting in emerging growth opportunities, particularly focusing on new customers for QuantaFlo both for PAD and HD. This broadening of our customer base may prove to show the tremendous promise and the exciting potential that we believe is in our company's future.”

Research

Fri, 26 Jul 2019 04:00:00 GMT

Semler Scientific (OOTC:SMLR) ($50.00; $322.5M market cap), a company that offers technology and software solutions to healthcare providers, announced Q2 2019 results:

Sales of $7.9 million vs $5.5 million in the prior year
EPS of $0.32 vs $0.19 in the prior year

"Our vascular testing product and data services are intended to help our customers solve problems encountered by underserved communities, diabetic populations, women and the elderly, among others," said Doug Murphy-Chutorian, M.D., chief executive officer ("CEO") of Semler Scientific. "We believe that early identification of chronic disease and preventive healthcare delivers clinical benefits and cost-effective value to patients at risk, especially those people who are neglected or unrecognized by current practices."

"We are pleased with the continued growth of our current book of business and with the inroads we are making with new customers. We believe we are well positioned to handle increased order sizes to satisfy future demand for our QuantaFlo™ product. Our two largest customers comprise 51% and 15% of quarterly revenues. License revenues were approximately $5.4 million, variable priced revenues were approximately $2.3 million and equipment sales were $306,000," said Dr. Murphy-Chutorian.

In 2019, Semler Scientific expects continued to experience profitability and generation of cash from operating activities, as well as increased spending to support anticipated growth. It is the company's intention to grow revenues at a faster rate than expenses and to remain profitable.”

You can see our full RFT here and an article a Geoinvesting Premium Member, Jakewell Parker, wrote about the company here.

Research

Mon, 14 Jan 2019 16:26:43 GMT

Locked In Rest of SMLR Gains

In September, we mentioned that we had locked in some gains from our original Semler Scientific (OOTC:SMLR) ($38.05; $239.7M market cap) long call back in April of 2018. On April 30, 2018, we issued our RFT (Reasons For Tracking) on SMLR, initiating a swing position in the stock. Shares were trading at $8.30 at the time.

We have now locked in the rest of our gains, closing out the position with shares up 358% from our initial long call.

You can see our full coverage on SMLR here.

Research

Fri, 26 Oct 2018 14:27:00 GMT

Semler Scientific (OOTC:SMLR) ($36.00; $226.5M market cap), a company that offers technology and software solutions to healthcare providers, announced Q3 2018 results:

Sales of $5.5 million vs $3.6 million in the prior year; slightly below analyst estimates of $5.7 million
EPS of $0.19 vs a loss of $0.01 in the prior year and ahead of analyst estimates of $0.15

"For the remainder of 2018 and continuing in 2019, Semler Scientific expects continued profitability and cash generated from operating activities. It is the company's intent to grow revenues at a faster rate than expenses and to remain profitable."

"Our goals are to work with the healthcare industry to reduce avoidable healthcare costs and improve health outcomes of patients," said Dr. Murphy-Chutorian. "We believe that earlier recognition of peripheral artery disease leads to early preventive care and the reduction of the risk of heart attack, stroke and amputation."

You can see our full coverage on SMLR here, including our initial call to action buy when stock was trading at $8. While we locked in some gains in early September, we still hold a long position.

Research

Mon, 10 Sep 2018 14:27:31 GMT

We decided to take some gains in Semler Scientific (OOTC:SMLR). The stock was up over 9% on Friday and closed the day at $29.69. On April 30, 2018, we issued our RFT (Reasons For Tracking) on SMLR, initiating a swing position in the stock. Shares were trading at $8.30 at the time. In mid-May, we moved SMLR from a swing trade position to our selected long holdings due to strong Q1 results.

Research

Tue, 31 Jul 2018 15:41:52 GMT

Semler Scientific (OOTC:SMLR) ($17.5; $104.2M market cap), a company that offers technology and software solutions to healthcare providers, announced Q2 2018 results:

Sales of $5.4 million vs $2.5 million in the prior year
EPS of $0.19 vs a loss of $0.16 in the prior year

"We believe that the achievement of healthier clinical outcomes for their patients is motivating healthcare providers to increase use of our products," said Doug Murphy-Chutorian, M.D., chief executive officer of Semler Scientific. "Our customer base is expanding, and established customers are ordering more product from us.

For the remainder of 2018, Semler Scientific expects to see continued profitability and cash generated from operating activities. The company believes expenses will continue to increase as the business expands due to increased use of its products. It is the company's intent to grow revenues at a faster rate than expenses and to remain profitable.

We believe our products will help reduce avoidable healthcare costs and improve health outcomes of patients," said Dr. Murphy-Chutorian. "The clinical strategy is to identify patients with peripheral artery disease who might benefit from early preventive care that is intended to reduce the risk of heart attack, stroke and amputation."

On April 30, 2018, we issued our RFT (Reasons For Tracking) on SMLR, initiating a swing position in the stock. Shares were trading at $8.30 at the time. In mid-May, we moved SMLR from a swing trade position to our selected long holdings due strong Q1 results. Yesterday, shares hit a new 52 week high of $18.30. We’ll keep you posted on our position going forward.

Research

Tue, 15 May 2018 14:35:54 GMT

Semler Scientific, Inc. (SMLR) ($11.87; $70.6M market cap) aims to provide technology and software solutions to improve the clinical effectiveness and efficiency of healthcare providers. Yesterday, we moved SMLR from a swing trade to a selected long position. We were able to speak with management once again yesterday and we asked them to address concerns and commentary that one of their competitors is publishing on its site. A precursory glance at the these concerns could cause some to believe that SMLR’s QuantaFlo product is being marketed for uses outside of the scope of its FDA medical device clearance approval.

Upon further examination, it seems that the competitor is basically trying to say that their product is better as it can be used under certain medicare reimbursement codes and it can be used as a diagnostic tool, things that SMLR cannot claim. However, SMLR management claims it is not marketing or promoting its device to be used under codes not indicated in its FDA clearance. Furthemore, it is very clear in its filings that QuantaFlo is not being marketed to directly diagnose Pulmonary Artery Disease (PAD). The diagnosis is left up to the doctor; QuantaFlo aids doctors in making their decisions.

We will continue our due diligence in to this matter.

Research

Mon, 14 May 2018 14:50:58 GMT

Moving SMLR From Swing Trade to Selected Long Holdings

On April 30, 2018 we issued our RFT (Reasons For Tracking) on SMLR which can be seen here, initiating a swing position in the stock. Shares were trading at $8.30 at the time of the RFT. After the company reported strong Q1 2018 earnings, the stock has been hitting new highs, reaching $11.55 late last week.

Due to the strong quarter, we have decided to move SMLR off the swing trade screen to our selected long positions. We have a planned follow up interview later this week which we hope will help support and galvanize this decision.

Research

Tue, 01 May 2018 14:46:19 GMT

Semler Scientific, Inc. (SMLR) ( $8.71; $51.7M market cap) aims to provide technology and software solutions to improve the clinical effectiveness and efficiency of healthcare providers. Yesterday we offered our reasons for tracking on SMLR which can be seen here, and initiated a swing position in the stock ahead of earnings this morning. They announced strong Q1 2018 results:

Sales of $4.4 million vs $2.0 million in the prior year
EPS of $0.12 vs a loss of $0.17 in the prior year

Quotes from management:

"Once again, we generated a quarterly profit from our recurring revenue business model," said Doug Murphy-Chutorian, M.D., chief executive officer of Semler. "This is the second consecutive profitable quarter in the company's history."

For the remainder of 2018, the Company expects to see continued profitability and cash generated from operating activities. The Company believes expenses will continue to increase as the business expands. It is the Company's intent to grow revenues at a faster rate than expenses and to remain profitable.

"Identifying patients with peripheral artery disease who might benefit from early preventive care should reduce the risk of heart attack, stroke and amputation," said Dr. Murphy-Chutorian. "For this reason, we believe our products may help reduce avoidable healthcare costs and improve health outcomes of patients."

Reasons For Tracking

Mon, 30 Apr 2018 04:00:00 GMT

Semler Scientific, Inc. (SMLR) ( $8.30; $50M market cap) aims to provide technology and software solutions to improve the clinical effectiveness and efficiency of healthcare providers. The company currently derives its revenue from selling its Quantaflo product to aid in the diagnosis of Vascular Disease and operating an online platform called WellChec that provides insurance companies with data analytics services.

We are intrigued by the progress the company has made since going live in 2011, its underserved market opportunity, and its recurring revenue model. This is one case where a new technology is replacing an inefficient “old school” solution.

We urge you to read the caveats at the end of this article. Specifically, we are still digging into the marketing material of one of SMLR’s competitors which talks about reasons that its product is superior to SMLR’s.

Putting this caveat aside for the time being, we feel SMLR may have reached a growth inflection point.

See our full reasons for tracking here.

Research

Wed, 02 Dec 2015 16:36:31 GMT

Semler Scientific, Inc. is a medical risk assessment company. The Company develops, manufactures and markets products that assist healthcare providers in monitoring patients and evaluating chronic diseases. The Company markets and licenses FloChec, which is a United States Food and Drug Administration (FDA) cleared product. FloChec is a four-minute in-office blood flow test. FloChec is used in the office setting to allow providers to measure arterial blood flow in the extremities and is a tool for internists and primary care physicians to conduct blood flow measurements. It offers FloChec product to cardiologists, internists, nephrologists, endocrinologists, podiatrists and family practitioners. The Company's FloChec features a sensor clamp that is placed on the toe or finger much like pulse oximetry devices. The Company provides FloChec product and services through salespersons and through its distributor.

In April 2015, the company announced the launch of its multi-test service offering, WellChec™, to more comprehensively evaluate patients for chronic disease.